Topic

Medicare Part D

Part D formulary design, IRA negotiated prices, out-of-pocket caps, LIS/Extra Help, and Medicare drug coverage policy.

4 articles·Lives underPricing & Access Policy·Last updated 2026-05-21

Policy· May 21, 2026 · 8 min read

Medicare Part D redesign 2025-2026: what the IRA changed, what it costs, and what commercial teams should monitor

The Inflation Reduction Act eliminated the Part D donut hole, capped out-of-pocket drug spending at $2,100 for 2026, and restructured cost-sharing across three phases....

By Ran Chen#Medicare Part D #IRA Negotiation #Payer Policy

Pricing & Access· May 18, 2026 · 11 min read

Jardiance vs Farxiga: label, access, and payer coverage compared

Jardiance (empagliflozin) and Farxiga (dapagliflozin) are the two most prescribed SGLT2 inhibitors in the US, each with landmark cardiovascular and kidney outcome data....

By Ran Chen#SGLT2 Inhibitor #Payer Policy #Coverage Access

Pricing & Access· May 17, 2026 · 10 min read

Farxiga coverage guide: formulary, prior authorization, and what access teams should know

Farxiga (dapagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. This guide maps FDA indications, dosing, formulary...

By Ran Chen#SGLT2 Inhibitor #Formulary #Prior Authorization

Pricing & Access· May 17, 2026 · 9 min read

Jardiance coverage guide: formulary, prior authorization, and what access teams should know

Jardiance (empagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. This guide maps FDA indications, dosing,...

By Ran Chen#SGLT2 Inhibitor #Formulary #Prior Authorization